Trial Profile

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Giant cell tumours; Large cell carcinoma; Neuroendocrine carcinoma; Penile cancer; Prostate cancer; Renal cell carcinoma; Squamous cell cancer; Testicular cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms ICONIC

Most Recent Events

13 Feb 2025 Planned End Date changed from 28 Feb 2025 to 28 Feb 2026.
13 Feb 2025 Planned primary completion date changed from 28 Feb 2025 to 28 Feb 2026.
08 Jun 2024 Planned number of patients changed from 224 to 314.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com